About Chembuild Pharma
Chembuild Pharma is a company based in India. The company has 1 employees. Chembuild Pharma offers products and services including Acebutolol Impurity B and Acesulfame Potassium Impurity B.
- Headquarter India
- Employees 1
- SectorsHealthcare
- Phone•••• ••••
- Legal Name Chembuild Pharma Private Limited
- Date of Incorporation 02 Jan, 2021
- Jurisdiction Hoshiarpur, Punjab, India
- Annual Revenue₹0.33 Cr
FY 2025 · +68% YoY
- Net Profit₹0.02 Cr
FY 2025 · 7% margin
- EBITDA₹0.03 Cr
FY 2025 · 8% margin
- Employee Count1
Associated legal entities of Chembuild Pharma
Chembuild Pharma operates through Chembuild Pharma Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Chembuild Pharma Private Limited CIN U24100PB2021PTC052546 | Active | 02 Jan 2021 | Hoshiarpur, Punjab | ₹0.3 Cr | – | 2 | View details |
Products & Services of Chembuild Pharma
Chembuild Pharma offers a comprehensive portfolio of products and services, including Acebutolol Impurity B and Acesulfame Potassium Impurity B.
Acebutolol Impurity B is manufactured and supplied for use in pharmaceutical applications
Acesulfame Potassium Impurity B is provided for research and quality control purposes in the industry
Board of directors of Chembuild Pharma Private Limited (Chembuild Pharma)
Chembuild Pharma Private Limited is the primary company behind Chembuild Pharma. The board of Chembuild Pharma Private Limited currently have 2 directors; the longest-serving is Lovenish Singh Sandhu, appointed in 2021.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Lovenish Singh Sandhu DIN 09017823 | Director | 02 Jan 2021 | 5 yrs 9 mo | Chembuild Pharma Private Limited |
| Anju DIN 09017824 | Director | 02 Jan 2021 | 5 yrs 9 mo | Chembuild Pharma Private Limited |
Financials of Chembuild Pharma
Figures of Chembuild Pharma Private Limited, the primary company behind Chembuild Pharma, for FY 2025. Revenue was ₹0.33 Cr (+68% year on year). Net profit was ₹0.02 Cr (7% margin). EBITDA was ₹0.03 Cr (8% margin). Revenue has grown at a compounded annual rate of +98% over three years.
- ₹0.33 CrRevenue · FY 2025 · +68% YoY
- ₹0.02 CrNet profit · 7% margin
- ₹0.03 CrEBITDA · 8% margin
- ₹0.00 CrPaid-up capital
- +98%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Chembuild Pharma Private Limited are on its company page.
Detailed financial statements for Chembuild Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Chembuild Pharma
10 companies that operate in the same segment as Chembuild Pharma (Toxicology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutic solutions for food allergies are developed via antibody platforms. | 2019 | San Francisco, California, United States | USD 75 M | – | – | |
Therapeutics for substance use disorders, including opioid-related conditions, are developed. | 2020 | Oakland, California, United States | USD 70 M | – | – | |
Drug delivery solutions via single-walled carbon nanotubes are offered. | 2008 | Houston, Texas, United States | USD 2.5 M | USD 5.07 M | 9 | |
Non-invasive drug testing technology is developed using fingerprints. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 25.71 M | – | – | |
Provides toxicology, chemistry, and consultancy services for agrochemical industries. | 2020 | Vapi, Gujarat, India | – | – | – | |
Instruments for rapid human DNA identification are developed. | 2006 | Pleasanton, California, United States | USD 92.06 M | USD 22.5 B | 78 | |
Oral therapies for snake bite treatment are developed. | 2015 | Corte Madera, California, United States | USD 16.48 M | – | – | |
Quantitative urine drug testing is provided for patient monitoring. | 2011 | San Diego, California, United States | – | – | 358 | |
Point-of-care platforms for heavy metal toxicity diagnostics are developed. | 1968 | Billerica, Massachusetts, United States | USD 34 M | – | – | |
Real-time trace gas analysis solutions are delivered using SIFT-MS technology. | 2002 | Christchurch, New Zealand | USD 11.9 M | USD 23.52 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Chembuild Pharma
Chembuild Pharma is headquartered in India.
Chembuild Pharma has 1 employees.
The primary company behind Chembuild Pharma, Chembuild Pharma Private Limited, reported revenue of ₹0.33 Cr for FY 2025, up 68% year on year.
Chembuild Pharma Private Limited is recognized as a supplier of pharmaceutical impurities that are delivered to various sectors including the pharmaceutical industry and research institutes. It was established in 2021 in Hoshiarpur, Punjab, India, with operations involving 25 employees who facilitate high-purity products for analytical research. The company is associated with API manufacturers and biotechnology firms, ensuring products are provided within committed timelines. Impurities for drugs like Acebutolol and Acesulfame are offered to meet global demands in a reliable manner.
Chembuild Pharma offers Acebutolol Impurity B and Acesulfame Potassium Impurity B.
Chembuild Pharma operates through Chembuild Pharma Private Limited.
The legal entities of Chembuild Pharma currently have 2 directors, including Lovenish Singh Sandhu, Anju.